Carcinoma, hepatocellular
Clinical trials for Carcinoma, hepatocellular explained in plain language.
Never miss a new study
Get alerted when new Carcinoma, hepatocellular trials appear
Sign up with your email to follow new studies for Carcinoma, hepatocellular, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Liver cancer patients get immunotherapy before surgery in new trial
Disease control Stopped earlyThis study tested giving immunotherapy drugs before surgery to people with liver cancer that could be removed. The goal was to see if these drug combinations could shrink the tumor or eliminate it before the operation. 62 participants took part in this early-phase trial, which ha…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Promising combo therapy for incurable liver cancer shows potential in phase 3 trial
Disease control Stopped earlyThis study tested whether adding two drugs (lenvatinib and pembrolizumab) to a standard liver cancer treatment called TACE helps people with liver cancer that cannot be removed by surgery. About 479 participants received either the drug combo plus TACE or TACE alone. The goal was…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Liver cancer trial tests new chemo combo without embolization
Disease control Stopped earlyThis phase 2 trial tested a liver-directed chemotherapy using idarubicin mixed with lipiodol (a fatty contrast agent) injected directly into the liver artery. The goal was to see if this could control non-spreading liver cancer in 44 patients with cirrhosis. The study was termina…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase 2 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Liver cancer drug combo put to the test – but trial stops early
Disease control Stopped earlyThis phase 3 trial compared a combination of two drugs (regorafenib and pembrolizumab) with standard locoregional therapies (TACE or TARE) as a first treatment for intermediate-stage liver cancer that has spread beyond certain limits. The study aimed to enroll about 496 people bu…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase 3 • Sponsor: Translational Research in Oncology • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Radioactive beads aim to shrink untreatable liver tumors
Disease control Stopped earlyThis early trial tested the safety and effectiveness of radioactive beads (Holmium-166 microspheres) in 4 adults with liver cancer that could not be removed by surgery or transplant. Participants first received a small scout dose to check for proper placement, then a personalized…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 26, 2026 19:18 UTC
-
Radiation therapy study seeks immune clues in blood
Knowledge-focused Stopped earlyThis study followed 28 adults with liver, colorectal, melanoma, or kidney cancers who received high-dose radiation therapy. Researchers collected blood samples before, during, and after treatment to track immune cells and other markers. The goal was to learn how the immune system…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC